Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) EBIT (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed EBIT for 5 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 202.43% year-over-year to $19.8 million, compared with a TTM value of $77.2 million through Dec 2025, up 269.28%, and an annual FY2025 reading of $77.2 million, up 269.28% over the prior year.
  • EBIT was $19.8 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $24.0 million in the prior quarter.
  • Across five years, EBIT topped out at $46.4 million in Q3 2022 and bottomed at -$49.3 million in Q1 2021.
  • Average EBIT over 5 years is -$7.0 million, with a median of -$10.3 million recorded in 2023.
  • The sharpest move saw EBIT plummeted 23925.93% in 2024, then soared 17330.77% in 2025.
  • Year by year, EBIT stood at -$36.1 million in 2021, then surged by 116.74% to $6.0 million in 2022, then tumbled by 98.66% to $81000.0 in 2023, then tumbled by 23925.93% to -$19.3 million in 2024, then soared by 202.43% to $19.8 million in 2025.
  • Business Quant data shows EBIT for KNSA at $19.8 million in Q4 2025, $24.0 million in Q3 2025, and $20.2 million in Q2 2025.